Home - Grand Pharma Group

About: us

Learn more

Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited

International pharmaceutical enterprises of scientific and technological innovation

Grand Pharmaceutical Group Co., Ltd. (stock code: 00512. HK) is a research-based international pharmaceutical enterprise that specialises in pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology and biotechnology.

9 +

R&D Centers

770 +

R&D People

147 +

Projects in Progress

News: Center

Learn more

Company News Media Coverage

The World’s First Nasal Spray Product of Grand Pharma for the Treatment of Dry Eye Disease, OC-01, Achieves the First Batch of Commercial Prescriptions After Its Official Approval in Mainland China

A New Indication of Grand Phamra’s Globally Innovative Radioactive Product SIR-Spheres® Y-90 Resin Microsphere Injection Is Officially Approved by the FDA Ahead of Schedule

Grand Pharma’s Global Innovative Ophthalmic Drug CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial

Global R&D Map

International R&D Center in Optics Valley, Wuhan

Technical Support for High-end Preparations

R&D Base in Canada (Progressing)

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment

R&D Base in Germany (Progressing)

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment

Equipment R&D and Production Base in Changzhou

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment

Glycomics R&D Center in Australia

Glycomics Technology Platform (Antiviral Drugs)

Boston R&D Center in USA

DNA Technology (Tumor DNA Immunotherapy)

R&D Base in Italy (Progressing)

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment

Active Equipment R&D and Production Base in Optics Valley, Wuhan

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment

Grand Pharmaceutical-Shandong University Radiopharmaceutical Research Institute in China

RDC technology platform

mRNA R&D Center in Nanjing

mRNA Technology Platform

CardioNavi’s R&D Center in Shanghai, China

RDC technology platform

Radiopharmaceutical R&D Center in Chengdu, China (Under Construction)

RDC technology platform

Internationalization

Learn more

Dare to be the first and share the success

Dare to be the first and share the success

In recent years, Grand Pharma has deployed a series of innovative pharmaceutical products with broad market in the United States, Australia, Germany and other countries. Our Group has established strong partnerships with the world's leading pharmaceutical companies, universities and research institutes, and achieved a rich and diversified product pipeline in a range of medical therapeutic areas. Grand Pharma has already invested and operated 5 R&D technology platforms and 8 R&D centres worldwide.

Core Business Areas

ENT Segment

Respiratory and Critical and Severe Disease Segment

Cerebro-cardiovascular Segment

Pharmaceutical Raw Materials Segment

mRNA platform

Nuclear Medicine Anti-tumor Diagnosis and Treatment Segment

Cerebro-cardiovascular Precision Interventional Diagnosis and Treatment Segment

Amino Acids Segment

PHARMACEUTICAL TECHNOLOGY

NUCLEAR MEDICINE ANTI-TUMOR DIAGNOSIS AND TREATMENT AS WELL AS CEREBRO- CARDIOVASCULAR PRECISION INTERVENTIONAL DIAGNOSIS AND TREATMENT TECHNOLOGY

BIOTECHNOLOGY

About Grand Pharma

Company Spirit Dare to be the first and share the success

Contact Grand Pharma

Address 23/F, Chengshi Plaza, No. 160 Qiaokou Road, Wuhan